

1 **In silico study on Spice-derived antiviral phytochemicals against**  
2 **SARS-CoV-2 TMPRSS2 target**

3 Pradeep Kumar Yadav<sup>γ\*</sup>, Amit Jaiswal<sup>γ<sup>1</sup></sup> and Rajiv Kumar Singh

4

5 Bioinformatics Centre, Faculty of Life Science, Rajiv Gandhi University, Rono Hills, Doimukh,  
6 Arunachal Pradesh, India 791112.

7 <sup>γ</sup> These authors contributed equally

8

9 \* [yadavpradeep755@gmail.com](mailto:yadavpradeep755@gmail.com)

10

## 11 **Highlights**


- 12 • TMPRSS2 facilitate the entry of SARS-CoV-2 in the host cell
- 13 • Spices have numerous potent anti-viral phytochemicals
- 14 • The study identified the phytochemicals (BDMC, carvacrol and thymol) as potent  
15 inhibitor candidates of TMPRSS2

## 16 **Abstract**

17 Corona Virus Disease (COVID-19) caused by Severe Acute Respiratory Syndrome Coronavirus  
18 2 (SARS-CoV-2) is a pandemic that has claimed so far over half a million human life across the  
19 globe. Researchers all over the world are exploring various molecules including phytochemicals  
20 to get a potential anti-COVID-19 drug. Certain phytochemicals present in some spices are  
21 claimed to possess antiviral, anti-bacterial, and anti-fungal properties. Hence, an *in-silico* study  
22 was done by selecting eighteen well reported antiviral phytochemicals from some spices  
23 commonly used in Indian kitchen viz. *Curcuma longa* (Turmeric), *Nigella sativa* (Black cumin),  
24 *Piper nigrum* (Black pepper), *Trachyspermum ammi* (Carom) and *Zingiber officinale* (Ginger) to  
25 find out whether they can prevent SARS-CoV-2 infection. Firstly, we predicted the structure of  
26 TMPRSS2 (transmembrane protease serine 2), a host protein that truncates spike protein of  
27 SARS-CoV-2 thereby facilitating its endocytosis, and then docked against its catalytic domain  
28 the selected phytochemicals and camostat (a well-known synthetic inhibitor of TMPRSS2).  
29 Thereafter, stability of seven best docked phytochemicals and camostat were scrutinized by  
30 Molecular Dynamic Simulation (MDS). MDS analysis indicated bisdemethoxycurcumin  
31 (BDMC), carvacrol and thymol as better inhibitors than the camostat due to their stable binding  
32 with TMPRSS2 in its oxyanion hole and inducing subtle modification in the spatial arrangement

33 of the catalytic triad residues. Among these three phytochemicals, carvacrol appeared to be the  
34 best inhibitor, followed by BDMC, whereas thymol was least effective.

### 35 Graphical abstract



36

37 **Keywords:** SARS-CoV-2, COVID-19, TMPRSS2 inhibitor, Spices, Antiviral

38 Phytochemical, Molecular Dynamics Simulation

39 **Running Title:** Phytochemicals from Spices as natural drug candidates for Covid-19

## 41 **Introduction**

42 The deadly pandemic pneumonia like Corona Virus Disease (COVID-19) caused by Severe  
43 Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) [1, 2] has spread worldwide with 10  
44 million population affected including around half a million succumbing to death [3]. Presently,  
45 in absence of any known cure for the disease, tremendous efforts are on all over the world to find  
46 out an effective drug from different sources including phytochemicals [4-6]. Certain drugs such  
47 as Remdesivir, Favipiravir, etc. are currently under clinical trials in the fight against SARS-Cov-  
48 2 [7].

49 The SARS-CoV-2 belongs to Coronavirus family (Coronaviridae), a cluster of viruses mainly  
50 hosted by bats [8]. Three viruses of this family, Middle-East Respiratory Syndrome Coronavirus  
51 (MERS-CoV), Severe Acute Respiratory Syndrome Coronavirus (SARS-CoV) and SARS-CoV-  
52 2) are reported to have crossed the species barrier and become deadly for humans since the dawn  
53 of the 21st century [9-11]. Entry of these viruses into the host cell is facilitated by the binding of  
54 their spike proteins (a highly glycosylated surface protein) to the cellular membrane receptor.  
55 The spike protein of SARS-CoV and the SARS-CoV-2 binds to the host receptor called  
56 Angiotensin-converting enzyme 2 (ACE2), whereas in case of MERS-CoV, it binds to dipeptidyl  
57 peptidase-4 [12]. It is also reported that infection gradient of SARS-CoV-2 in the respiratory  
58 tract is correlated with expression of ACE2 with occurs maximally in the nose and bronchus and  
59 decreases throughout the lower respiratory tract [13]. The spike protein of SARS-CoV-2 has two  
60 domains: S1 (receptor binding domain) and S2 (membrane fusion domain); and a cleavage  
61 between these domains by the host transmembrane protease serine 2 (TMPRSS2) is a pre-  
62 requisite for the entry of these viruses through endocytosis into the host cell [14-16].

63 Iwata-Yoshikawa et al. have reported a reduction in SARS-CoV and MERS-CoV infection in  
64 the absence of TMPRSS2 in mouse [16, 17]. Matsuyama et al. found enhanced infection rates  
65 while activating TMPRSS2 [18]. Hoffmann et al. has reported that inhibition of TMPRSS2 by  
66 camostat mesylate, a synthetic inhibitor approved for clinical use, blocks the entry of SARS-  
67 CoV-2 into the host cell [16, 17]. These studies highlight that TMPRSS2 is one of the prime  
68 targets whose inhibition can prevent spread of these viruses within the host.

69 Some traditional spices used routinely across the Indian sub-continent are well known for their  
70 medicinal values, antiviral properties and the least side effects [19-25]. Therefore, in the present  
71 study, we selected eighteen well-known antiviral phytochemicals (Table 1) present in some  
72 commonly used spices in Indian kitchens viz. *Curcuma longa* (Turmeric), *Nigella sativa* (Black  
73 cumin), *Piper nigrum* (Black pepper), *Trachyspermum ammi* (Carom), *Zingiber officinale*  
74 (Ginger) and camostat, and carried out Molecular Dynamic Simulations (MDS) analysis after  
75 docking them individually against our predicted three dimensional (3D) molecular model of  
76 TMPRSS2 for identifying potential phytochemicals that can alter the catalytic domain of  
77 TMPRSS2.

## 78 **Materials and Methods**

### 79 **Structure prediction and analysis of TMPRSS2**

80 The protein sequence of TMPRSS2 (Uniprot ID:O15393) was collected from Uniprot [26] and  
81 NCBI blast search was performed against protein data bank (PDB) to find out a suitable structure  
82 for the study. The best available structure showed a sequence identity of 42.56% and a query  
83 coverage of only 48%. In absence of any deposited structure, the structure prediction for  
84 TMPRSS2 was done by an online web server Phyre2 based on multi-template and *ab-initio* [27].

85 The PDB model was then verified by getting Ramchandran plot from an online web server  
 86 Procheck [28, 29] . Once the structure was validated, the catalytic domain was considered for  
 87 molecular docking followed by MDS analysis.

## 88 Docking studies

89 Anti-viral phytochemicals reported from the spices (*Z. officinale*, *C. longa*, *T. ammi*, *N. sativa*  
 90 and *P. nigrum*) were obtained through literature review (Table 1) and their three-dimensional  
 91 structures were collected from the Pubchem database [30].

92  
 93 **Table 1:** Phytochemicals from spices used docking with TMPRSS2

Sl. No.	Spice Name	Antiviral Compound	PubChem ID	References
1.	<i>Trachyspermum ammi</i> (Carom )			
		Thymol	6989	[23, 31-33]
		p-cymene	7463	[34, 35]
		$\gamma$ -terpinene	7461	[31]
2.	<i>Curcuma longa</i> (Turmeric)			
		Curcumin	969516	[36]
		Bisdemethoxycurcumin (BDMC)	5315472	[24, 36-38]
		Desmethoxycurcumin	5469424	[36]
		Tetrahydrocurcumin	124072	
3.	<i>Zingiber officinale</i> (Ginger)			
		[6]-Gingerol	442793	[25, 39-42]
		[8]-Gingerol	168114	

		[10]-Gingerol	168115	
		[6]-Shogaol	5281794	
		[8]-Shogaol	6442560	
		[10]-Shogaol	6442612	
4.	<i>Piper nigrum</i> (Black pepper)			
		$\beta$ -caryophyllene	5281515	[43]
		Limonene	22311	[44]
5.	<i>Nigella sativa</i> (Black cumin)			
		$\beta$ -pinene (also present in black pepper)	14896	[44]
		Carvacrol	10364	[45]
		Thymoquinone	10281	[46]

94

95

96 The modelled structure of TMPRSS2 was aligned with Thrombin (4UD9, a serine protease) to  
97 identify its active site and residues. The standard serine protease residue numbers, catalytic triad  
98 of active site residues, and oxyanion hole were also identified and located (Fig. 1A-C;  
99 Supplementary Fig. SF1). To know the binding site of the inhibitor, a 3D structure of Prostatin  
100 (3FVF, a serine protease) complexed with camostat (a well-known inhibitor of TMPRSS2) was  
101 analyzed [47]. The camostat structure was separated from 3FVF and included in the list of  
102 molecules to be docked with TMPRSS2 for comparative analysis. The co-ordinates of catalytic  
103 triad residues (His296, Asp345 and Ser441; residue number are as per TMPRSS2 sequence) and  
104 oxyanion hole of catalytic domain of TMPRSS2 were chosen as the binding site for docking

105 studies with a total of 18 phytochemicals along with camostat. For docking purpose, the  
106 preparation of ligand and protein molecules followed by docking search run and analysis were  
107 done by graphical user interface software “AutoDockTools1.5.7” [48]. Autogrid was used to  
108 attain grid box with dimension (56 x 32 x 62 Å<sup>3</sup>) and center at C $\alpha$  atom of Ser441. Further,  
109 autodock4.2 was used with lamarckian genetic algorithm to get the best docking conformations  
110 [49]. The complexes with the best conformations were put under MDS scrutiny.

111

## 112 **Molecular Dynamics Simulation (MDS) studies**

113 Gromacs molecular dynamics package [50] was employed to have an insight of the  
114 conformational changes in the catalytic domain of Tmprss2 in the apo-form and the holo-  
115 forms. The simulations were performed using GROMOS96-54a7 force field while TIP3P water  
116 model with cubic box was used for solvating the models. The topology of the ligands were  
117 obtained from the PRODRG server by submitting their structures [51]. The system’s total charge  
118 calculated was +1 which was neutralized using chloride counter-ions by replacing a water  
119 molecule. The steepest descent algorithm followed by the conjugate algorithm was utilized with  
120 50,000 steps energy minimization of the system. All the bond angles were restrained with the  
121 LINCS algorithm. Equilibration of the solvated system was performed with NVT (constant  
122 number of particles, volume and temperature) followed by NPT (constant number of particles,  
123 pressure and temperature) with 300K and 1.0 atm respectively. Finally, the pre-equilibrated  
124 systems were put on production run for 100ns. Final molecular dynamics trajectories were  
125 analyzed by GROMACS analysis packages and the graphs/plots were visualized in qtGrace. For  
126 determining the variations in binding energy throughout the trajectory for each complex, the  
127 frames at every 100ps were extracted and submitted to the online webserver “PRODIGY”[52].

128

## 129 **Dihedral PCA (dPCA) analysis**

130 Dihedral PCA (principal component analysis) was used to describe the high-amplitude concerted  
131 motion from the MD trajectories of protein based on eigenvectors calculated using covariance  
132 matrix [53, 54]. The dihedral angles of protein defined the atomic fluctuation throughout the MD  
133 simulation, and were described by the cosine values of the PC of covariance matrix. The cosine  
134 values checked whether the trajectory has ensembled enough to show the free energy landscape  
135 obtained from the dPCA analysis [55, 56]. The range of cosine value from 0 to 1 in the total time  
136 of MD simulation (T) is given by

$$137 \quad C_i = \frac{2}{T} \left( \int_0^T \cos\left(\frac{i\pi t}{T}\right) p_i(t) dt \right)^2 \left( \int_0^T p_i^2(t) dt \right)^{-1}$$

138 where  $p_i(t)$  is the  $i^{th}$  PC's value. Thus, absolute and sensitive parameters of trajectory was  
139 measured by getting numerous free-energy minima, which relates to conformations mapping  
140 with their respective energy basins as available in the free energy landscape of the selected PCs.  
141 Generally, the first few PCs contributions define nature of the protein. However, in most of the  
142 eigenvectors, the cosine values were close to one due to a large-scale motion in the protein  
143 dynamics, and, hence, not used [57, 58].


144

## 145 **Results and Discussion**

### 146 **Structure prediction and characterization of TMPRSS2**

147 The 3D model of TMPRSS2 obtained in the present study from Phyre2 webserver was  
148 manually analyzed. The domains of TMPRSS2 were identified as Low Density Lipoprotein

149 (LDL) domain (113-148), Scavenger Receptor Cysteine-Rich (SRCR) domain (149-242) and the  
150 Catalytic domain (255-492) (Fig. 1A) [59].




151  
152 **Fig. 1. Structural characterization of TMPRSS2.** (A) Different domains (indicated by  
153 different colors and residue numbers). (B) Predicted 3D structure (from Phyre webserver).  
154 Colors in the cartoon representation indicate the confidence of prediction. (C) Surface  
155 representation of complete TMPRSS2 (The catalytic domain is further zoomed to show catalytic  
156 triad residues and oxyanion hole).

157  
158 The catalytic domain was well predicted with high confidence (Fig. 1B) whereas  
159 prediction for non-catalytic regions comprising of LDL and SRCR domains showed a low  
160 confidence. The structure alignment of TMPRSS2 catalytic domain with the Thrombin showed  
161 Root Mean Square Deviation (RMSD) of 0.59 Å. The Ramachandran plot for the truncated  
162 catalytic domain of TMPRSS2 (265-492) from Procheck server showed 98% of the residues in

163 the allowed or the most favored regions whereas only one residue (Gln276) lay in the disfavored  
164 region (Supplementary Fig. SF2). Thus, the modelled structure was found suitable for further  
165 docking and MDS studies.

## 166 **Molecular docking studies**

167 Autodock results were analyzed in terms of low binding energy, high number of hydrogen-bonds  
168 and ligands docked-poses. The best docked poses of the top seven phytochemicals were selected  
169 (Supplementary Table ST1). The binding energy of these phytochemicals were better (lower)  
170 than camostat (Fig. 2, Table 2) and docked in the proximity of oxyanion hole/catalytic triad of  
171 the active site of TMPRSS2. The stability of the selected docked-poses for the molecule was  
172 tested by running MDS.



173  
 174 Fig. 2. **Docked poses of selected phytochemicals and interacting residues.** Picture in the center  
 175 shows the docked poses of phytochemicals with catalytic domain of TMPRSS2. (A-H) Non-  
 176 bonded interaction of each phytochemical. Dotted line in Red denotes hydrogen bond, Green  
 177 denotes Pi-Sigma Bonds, Brown denotes Alkyl bonds, Orange denotes Pi-Sulphur bonds and  
 178 Pink denotes Pi-Amide bonds. Binding energy scores are written beside the arrows.

179  
 180 **Table 1: Seven best phytochemicals with their binding energy and H-bond for the best**  
 181 **docked poses**

Phytochemical compound	CID	Binding Energy (kcal/mol)	H-bonds	Interacting Residues for H-bond
Thymoquinone	10281	-4.15	3	Ser436, Cys437,

				Gly472
Thymol	6989	-4.03	2	Gly464, Gly472
Carvacrol	10364	-3.9	1	Gly462
Caryophyllene	5281515	-3.79	0	None
Limonene	22311	-3.78	0	None
Bisdemethoxycurcumin (BDMC)	5315472	-3.71	1	Gln438
p-Cymene	7463	-3.58	0	None
Camostat (Reference Molecule)	5284360	-3.18	6	Ser436, Cys437, Gly438, Gly439, Ser441, Gly472

182


183

184

185 **MDS of Apo- and Holo- form of TMPRSS2**

186 **Root Mean Square Deviation (RMSD) and Root Mean Square Fluctuation (RMSF)**

187 Protein-RMSD and Ligand-RMSD averaged over 500 frames for both the apo-form and the  
188 holo-forms of TMPRSS2 (Catalytic domain) were monitored and the graphs are presented in Fig.  
189 3A and Fig. 3B respectively. The Protein-RMSD for TMPRSS2 apo-form showed a slight rise  
190 within initial 5ns and thereafter remained almost stable throughout the simulation showing only a  
191 slight fluctuation at 19ns and 60ns. The Protein-RMSD with thymol and carvacrol also showed  
192 stability except at 20ns for thymol and between 70-90ns for carvacrol. Further, except  
193 bisdemethoxycurcumin (BDMC), other ligands showed more RMSD fluctuation in comparison  
194 to the apo-form of TMPRSS2. High fluctuation in Protein-RMSD was observed in TMPRSS2  
195 with limonene, camostat, p-cymene, thymoquinone and caryophyllene. The Protein-RMSD of  
196 TMPRSS2 with camostat showed a continuous rise from around 3.0Å to 5.3Å within first 40ns  
197 and remained at around 5.0 Å with slight fluctuations afterwards.



198

199 Fig. 3. **Molecular Dynamics Simulation analysis of TMPRSS2.** (A) RMSD of the apo-form  
 200 and the holo-forms of TMPRSS2. (B) RMSD of the ligands. (C) RMSF of the apo-form and the  
 201 holo-forms of TMPRSS2. (D) Solvent Accessible Surface Area (SASA) each complex. (E)  
 202 Binding energy of each ligand throughout the trajectory. (F-J) Number of hydrogen bonds  
 203 between TMPRSS2 and ligands. Black line represents the apo-form and the colored lines  
 204 represent the holo-forms (assigned color for each ligand is given at the base).

205

206 High fluctuation in ligand-RMSD was observed in limonene, camostat, p-cymene, thymoquinone  
207 and caryophyllene against a very low fluctuation in thymol and carvacrol except towards the end  
208 of the simulation. On the other hand, BDMC-RMSD remained stable throughout the simulation  
209 with moderate fluctuations. Thus it can be concluded that the binding poses for BDMC,  
210 carvacrol and thymol are more stable in comparison to camostat and the rest four  
211 phytochemicals.

212 RMSF of TMPRSS2 for the apo-form and all holo-forms showed almost similar pattern with  
213 only a little difference. A major fluctuation was observed in loop regions in comparison to helix  
214 or sheets region (Fig. 3C).

215

### 216 **Solvent accessible surface area (SASA), Hydrogen bond (H-Bonds) and Binding energy** 217 **(BE)**

218 SASA was calculated for each frame throughout the MD trajectory for the apo-form and all the  
219 complexes, and plotted averaging over 500 frames (Fig. 3D). All the SASA started at around  
220  $130\pm 3\text{nm}^2$  and ended at around  $120\pm 5\text{nm}^2$ . For TMPRSS2 complexed with caryophyllene,  
221 SASA showed the highest fluctuation with a decrement of about  $10\text{nm}^2$  during first 30ns,  
222 followed by an increment of  $10\text{nm}^2$  in next 30ns, and again a decrement at the end of the  
223 trajectory. The possibility of a high fluctuation can be correlated with the change in position of  
224 caryophyllene as it moved away from the active site (Supplementary Fig. SF4). Both for  
225 limonene and p-cymene, the complexes showed a consistency in SASA with slight fluctuations.  
226 BDMC, carvacrol, camostat and thymoquinone showed a decrement in SASA within 20ns and  
227 thereafter remained almost stable throughout the trajectory. TMPRSS2, in the apo-form, and the

228 complex form with carvacrol showed similar curves around  $120\text{nm}^2$ . Its complexes with other  
229 ligands had the SASA curves within  $120\text{-}130\text{nm}^2$  which was more than the apo-form (Fig. 3D).  
230 The presence of H-bond between ligand and protein was observed for each frame throughout the  
231 simulation. Five phytochemicals viz. thymoquinone, thymol, carvacrol, camostat and BDMC  
232 formed Protein-ligand H-bond (Fig. 3F-3J) whereas other ligands did not show H-bonds. Both  
233 camostat and BDMC showed high number of H-bonds, with a maximum of six H-bonds and an  
234 average of 2 to 3 H-bonds throughout the simulation. Thymoquinone and thymol generally  
235 showed one H-bond but sometimes two H-bonds. For carvacrol, a consistency of two H-bonds  
236 was observed from 5ns to 43ns, and also after 85ns, but in the rest of the trajectory one H-bond  
237 was observed.


238 For accounting variations in the BE of each ligand throughout the MDS, the coordinates were  
239 extracted at every 100ps from the trajectory and submitted to the Prodigy server. The results  
240 have been presented in Fig. 3E. All phytochemicals showed better BE than camostat ( $-6.0$   
241  $\text{kcal/mol}$ ), and among them, BDMC showed the lowest average BE ( $-9.7 \text{ kcal/mol}$ ). A stability  
242 in the BE curve was observed for camostat, thymoquinone, carvacrol and BDMC from 25ns  
243 onwards till the end of the trajectory whereas caryophyllene, p-cymene and limonene showed  
244 fluctuations throughout the trajectory. In initial 20ns, there was a decrement in the BE for  
245 BDMC, carvacrol, thymol, p-cymene, whereas there was an increment for camostat,  
246 thymoquinone and caryophyllene.

## 247 **Dihedral principle component analysis (dPCA)**

248 dPCA was performed to understand the structural behavior of TMPRSS2 in both the apo-form  
249 and the holo-forms. The free energy landscape (FEL) was drawn using the largest two principle  
250 components with the cosine value less than 0.2 [55]. Analysis of FEL showed that the apo-form

251 and the complex of TMPRSS2 with thymol, carvacrol and BDMC have converged into a big low  
252 energy cluster symbolizing inter-convertible low energy conformational population, thus  
253 concluding that the protein has attained a stable form (Supplementary Fig. SF3). Other  
254 complexes could not attain stable conformations within 100ns as reflected by formation of either  
255 several small clusters (p-cymene) or several medium size low free energy conformational  
256 clusters (caryophyllene, thymoquinone, carvacrol, limonene and camostat). Thus, the coordinate  
257 from minima of the largest cluster was extracted for TMPRSS2 complexed with thymol,  
258 carvacrol and BDMC for the analysis of binding pose/location (Fig. 4, Supplementary Table  
259 ST2, ST3 & ST4), which was subsequently zoomed to observe non-bonded interactions.

260 Carvacrol was found to bind deep in the oxyanion hole with one H-bond and ten hydrophobic  
261 interactions. Thymol remained at the entry point of the oxyanion hole forming one H-bond and  
262 four hydrophobic interactions. On the other hand, BDMC as a larger molecule occupied the  
263 entire oxyanion hole with two H-bonds and five hydrophobic interactions.




264

265 Fig. 4. **Free Energy Landscape (FEL) plot of BDMC, carvacrol and thymol.** Representative  
 266 structures from the most populated low-energy cluster is shown to depict the binding pose.  
 267 Zoomed image depict non-bonded interaction of ligand with TMPRSS2. (Zoomed image has  
 268 been re-orientated for showing the best view).

269

## 270 **Influence of carvacrol, thymol, BDMC on the catalytic triad**

271 The distance between the  $C\alpha$  atoms of the catalytic triad residues of TMPRSS2 ( $C\alpha$ -His296,  $C\alpha$ -  
 272 Asp345 and  $C\alpha$ -Ser441) were also monitored throughout the simulation in both the apo-form and  
 273 the holo-form with carvacrol, thymol and BDMC (Fig. 5). A significant increment in the distance  
 274 between  $C\alpha$ -His296 and  $C\alpha$ -Ser441 as well as  $C\alpha$ -Asp345 and  $C\alpha$ -Ser441 was observed due to  
 275 binding of carvacrol. Thymol increased the distance between  $C\alpha$ -Asp345 and  $C\alpha$ -Ser441  
 276 whereas BDMC showed negligible change in  $C\alpha$  distance of the catalytic triad residues.



277

278 **Fig. 5. Distance between C $\alpha$  atoms of catalytic triad residues throughout the trajectory. (A)**  
 279 **C $\alpha$ -His296 and C $\alpha$ -Asp345 (B) C $\alpha$ -His296 and C $\alpha$ -Ser441 (C) C $\alpha$ -Asp345 and C $\alpha$ -Ser441.**  
 280 **Color depiction: Apo-form of TMPRSS2 (black line) and holo-form of TMPRSS2 with BDMC**  
 281 **(red line), carvacrol (cyan line) and thymol (blue line). The distance between catalytic triad**  
 282 **residues shows maximum deviation due to binding of carvacrol followed by thymol whereas the**  
 283 **least with BDMC.**

284

### 285 **Picking up of the best TMPRSS2 inhibitor**

286 Stable binding of ligands to oxyanion hole can block interaction of arginine of the substrate with  
287 the oxyanion hole which plays a crucial role in accommodating residue arginine of the substrate  
288 to ignite cleavage of its peptide bond.

289 On the basis of the results (stable RMSD, low binding energy, number of H-bonds throughout  
290 simulation and dPCA analysis), we conclude that the BDMC, carvacrol and thymol form stable  
291 binding with TMPRSS2 in the oxyanion hole and modified the spatial arrangement of the  
292 catalytic triad residues. The change in the spatial arrangement of the catalytic triad was the  
293 highest in carvacrol, followed by thymol, and the least with BDMC. However, BDMC being a  
294 large molecule could effectively shield the oxyanion hole. Levels of inhibition among stable  
295 bound molecules would be graded as: best carvacrol, then BDMC, and least thymol. Therefore,  
296 we conclude that blocking of TMPRSS2 by these phytochemicals is expected to prevent ACE2-  
297 and TMPRSS2-mediated cell entry of SARS-CoV-2 and other viruses into the host cells.

### 298 **Conclusion**

299 The *in-silico* study conducted to designate some potential antiviral phytochemicals present in  
300 some common spices used in Indian kitchens to inhibit the activity of TMPRSS2 included  
301 docking of phytochemicals with the catalytic domain of TMPRSS2 for specifying the best  
302 binding pose in terms of docked binding energy followed by MD simulation scrutiny and  
303 identified three potential antiviral phytochemicals namely carvacrol, thymol and BDMC found in  
304 *N. sativa*, *T. ammi*, and *C. longa* respectively which might be studied further as potential drug  
305 candidates against SARS-CoV-2.

## 306 **Acknowledgements**

307 Authors acknowledge Department of Biotechnology (DBT), Govt. of India for providing  
308 financial support to the Bioinformatics Centre of the University where this work was carried out,  
309 and also to the DBT electronic library consortium for providing access to the e-resources. First  
310 author thanks the DBT for providing Post-doctoral Fellowship. Critical suggestions during the  
311 finalization of the manuscript from Dr. K. C. Mishra, a faculty of the University are  
312 acknowledged.

## 313 **Abbreviations**

314 COVID-19 = Corona Virus Disease

315 SARS-CoV-2 = Severe Acute Respiratory Syndrome Coronavirus 2

316 TMPRSS2 = transmembrane protease serine 2

317 BDMC = bisdemethoxycurcumin

318 MDS = Molecular Dynamic Simulation

319 ACE2 = Angiotensin-converting enzyme 2

320  $d$ PCA = Dihedral PCA

321 RMSD = Root Mean Square Deviation

322

323

## 324 **References**

325

326 1. Lu, R., et al., *Genomic characterisation and epidemiology of 2019 novel coronavirus: implications*  
327 *for virus origins and receptor binding*. The Lancet, 2020. **395**(10224): p. 565-574.

328 2. Chan, J.F.-W., et al., *A familial cluster of pneumonia associated with the 2019 novel coronavirus*  
329 *indicating person-to-person transmission: a study of a family cluster*. The Lancet, 2020.  
330 **395**(10223): p. 514-523.

331 3. WHO, *Coronavirus disease (COVID-2019) situation reports - 162*. 2020: World Health  
332 Organization.

333 4. Prasad, A., M. Muthamilarasan, and M. Prasad, *Synergistic antiviral effects against SARS-CoV-2*  
334 *by plant-based molecules*. Plant Cell Reports, 2020.

335 5. Mani, J.S., et al., *Natural product-derived phytochemicals as potential agents against*  
336 *coronaviruses: A review*. Virus Res, 2020. **284**: p. 197989.

337 6. Orhan, I.E. and F.S. Senol Deniz, *Natural Products as Potential Leads Against Coronaviruses:*  
338 *Could They be Encouraging Structural Models Against SARS-CoV-2?* Nat Prod Bioprospect, 2020.

339 7. Costanzo, M., M. De Giglio, and G. Roviello, *SARS CoV-2: Recent Reports on Antiviral Therapies*  
340 *Based on Lopinavir/Ritonavir, Darunavir/Umifenovir, Hydroxychloroquine, Remdesivir,*  
341 *Favipiravir and Other Drugs for the Treatment of the New Coronavirus*. Current medicinal  
342 chemistry, 2020.

343 8. Forni, D., et al., *Molecular Evolution of Human Coronavirus Genomes*. Trends Microbiol, 2017.  
344 **25**(1): p. 35-48.

- 345 9. Zaki, A.M., et al., *Isolation of a novel coronavirus from a man with pneumonia in Saudi Arabia*. N  
346 Engl J Med, 2012. **367**(19): p. 1814-20.
- 347 10. Drosten, C., et al., *Identification of a novel coronavirus in patients with severe acute respiratory*  
348 *syndrome*. N Engl J Med, 2003. **348**(20): p. 1967-76.
- 349 11. Huang, C., et al., *Clinical features of patients infected with 2019 novel coronavirus in Wuhan,*  
350 *China*. Lancet, 2020. **395**(10223): p. 497-506.
- 351 12. Mou, H., et al., *The receptor binding domain of the new Middle East respiratory syndrome*  
352 *coronavirus maps to a 231-residue region in the spike protein that efficiently elicits neutralizing*  
353 *antibodies*. J Virol, 2013. **87**(16): p. 9379-83.
- 354 13. Hou, Y.J., et al., *SARS-CoV-2 Reverse Genetics Reveals a Variable Infection Gradient in the*  
355 *Respiratory Tract*. 2020.
- 356 14. Iwata-Yoshikawa, N., et al., *TMPRSS2 Contributes to Virus Spread and Immunopathology in the*  
357 *Airways of Murine Models after Coronavirus Infection*. J Virol, 2019. **93**(6).
- 358 15. Glowacka, I., et al., *Evidence that TMPRSS2 activates the severe acute respiratory syndrome*  
359 *coronavirus spike protein for membrane fusion and reduces viral control by the humoral immune*  
360 *response*. J Virol, 2011. **85**(9): p. 4122-34.
- 361 16. Hoffmann, M., et al., *SARS-CoV-2 cell entry depends on ACE2 and TMPRSS2 and is blocked by a*  
362 *clinically proven protease inhibitor*. Cell, 2020.
- 363 17. Iwata-Yoshikawa, N., et al., *TMPRSS2 contributes to virus spread and immunopathology in the*  
364 *airways of murine models after coronavirus infection*. Journal of virology, 2019. **93**(6): p. e01815-  
365 18.
- 366 18. Matsuyama, S., et al., *Enhanced isolation of SARS-CoV-2 by TMPRSS2-expressing cells*.  
367 Proceedings of the National Academy of Sciences, 2020. **117**(13): p. 7001-7003.

- 368 19. Vasanthi, H.R. and R.P. Parameswari, *Indian spices for healthy heart - an overview*. *Curr Cardiol*  
369 *Rev*, 2010. **6**(4): p. 274-9.
- 370 20. Chongtham, A. and N. Agrawal, *Curcumin modulates cell death and is protective in Huntington's*  
371 *disease model*. *Sci Rep*, 2016. **6**: p. 18736.
- 372 21. Saleem, U., et al., *Pharmacological Screening of Trachyspermum ammi for Antihyperlipidemic*  
373 *Activity in Triton X-100 Induced Hyperlipidemia Rat Model*. *Pharmacognosy Res*, 2017. **9**(Suppl  
374 1): p. S34-S40.
- 375 22. Singh, S., *From exotic spice to modern drug?* *Cell*, 2007. **130**(5): p. 765-8.
- 376 23. Alburn, H.E. and G. Greenspan, *Thymol as an anti-influenza agent*. 1972, Google Patents.
- 377 24. Chen, T.Y., et al., *Inhibition of enveloped viruses infectivity by curcumin*. *PLoS One*, 2013. **8**(5): p.  
378 e62482.
- 379 25. Rathinavel, T., et al., *Phytochemical 6-Gingerol—A promising Drug of choice for COVID-19*.
- 380 26. Consortium, U., *UniProt: a hub for protein information*. *Nucleic acids research*, 2015. **43**(D1): p.  
381 D204-D212.
- 382 27. Kelley, L.A., et al., *The Phyre2 web portal for protein modeling, prediction and analysis*. *Nature*  
383 *protocols*, 2015. **10**(6): p. 845.
- 384 28. Laskowski, R., M. MacArthur, and J. Thornton, *PROCHECK: validation of protein-structure*  
385 *coordinates*. 2006.
- 386 29. Ramachandran, G.N., *Stereochemistry of polypeptide chain configurations*. *J. Mol. Biol.*, 1963. **7**:  
387 p. 95-99.
- 388 30. Kim, S., et al., *PubChem Substance and Compound databases*. *Nucleic Acids Res*, 2016. **44**(D1): p.  
389 D1202-13.
- 390 31. Astani, A., J. Reichling, and P. Schnitzler, *Comparative study on the antiviral activity of selected*  
391 *monoterpenes derived from essential oils*. *Phytother Res*, 2010. **24**(5): p. 673-9.

- 392 32. Knight, V., et al., *Thymol suppression of protein synthesis in influenza virus-infected and*  
393 *uninfected chick embryo fibroblast cells*. Proc Soc Exp Biol Med, 1977. **155**(1): p. 128-36.
- 394 33. Wu, Q.F., et al., *Chemical compositions and anti-influenza activities of essential oils from Mosla*  
395 *dianthera*. J Ethnopharmacol, 2012. **139**(2): p. 668-71.
- 396 34. Marchese, A., et al., *Update on Monoterpenes as Antimicrobial Agents: A Particular Focus on p-*  
397 *Cymene*. Materials (Basel), 2017. **10**(8).
- 398 35. Sharifi-Rad, J., et al., *Susceptibility of herpes simplex virus type 1 to monoterpenes thymol,*  
399 *carvacrol, p-cymene and essential oils of Sinapis arvensis L., Lallelantia royleana Benth. and*  
400 *Pulicaria vulgaris Gaertn*. Cell Mol Biol (Noisy-le-grand), 2017. **63**(8): p. 42-47.
- 401 36. Anggakusuma, et al., *Turmeric curcumin inhibits entry of all hepatitis C virus genotypes into*  
402 *human liver cells*. Gut, 2014. **63**(7): p. 1137-49.
- 403 37. Mounce, B.C., et al., *Curcumin inhibits Zika and chikungunya virus infection by inhibiting cell*  
404 *binding*. Antiviral Res, 2017. **142**: p. 148-157.
- 405 38. Ting, D., et al., *Multisite inhibitors for enteric coronavirus: antiviral cationic carbon dots based on*  
406 *curcumin*. 2018. **1**(10): p. 5451-5459.
- 407 39. Kaushik, S., et al., *Anti-viral activity of Zingiber officinale (Ginger) ingredients against the*  
408 *Chikungunya virus*. Virusdisease, 2020: p. 1-7.
- 409 40. Chang, J.S., et al., *Fresh ginger (Zingiber officinale) has anti-viral activity against human*  
410 *respiratory syncytial virus in human respiratory tract cell lines*. J Ethnopharmacol, 2013. **145**(1):  
411 p. 146-51.
- 412 41. Imanishi, N., et al., *Macrophage-mediated inhibitory effect of Zingiber officinale Rosc, a*  
413 *traditional oriental herbal medicine, on the growth of influenza A/Aichi/2/68 virus*. Am J Chin  
414 Med, 2006. **34**(1): p. 157-69.

- 415 42. Rajagopal, K., et al., *Activity of phytochemical constituents of black pepper, ginger, and garlic*  
416 *against coronavirus (COVID-19): An in silico approach*. 2020. **9**(5): p. 43.
- 417 43. Astani, A., J. Reichling, and P. Schnitzler, *Screening for antiviral activities of isolated compounds*  
418 *from essential oils*. Evid Based Complement Alternat Med, 2011. **2011**: p. 253643.
- 419 44. Astani, A. and P. Schnitzler, *Antiviral activity of monoterpenes beta-pinene and limonene against*  
420 *herpes simplex virus in vitro*. Iran J Microbiol, 2014. **6**(3): p. 149-55.
- 421 45. Sanchez, C., R. Aznar, and G. Sanchez, *The effect of carvacrol on enteric viruses*. Int J Food  
422 Microbiol, 2015. **192**: p. 72-6.
- 423 46. Umar, S., et al., *Synergistic effects of thymoquinone and curcumin on immune response and anti-*  
424 *viral activity against avian influenza virus (H9N2) in turkeys*. Poult Sci, 2016. **95**(7): p. 1513-1520.
- 425 47. Spraggon, G., et al., *Active site conformational changes of prostaticin provide a new mechanism of*  
426 *protease regulation by divalent cations*. Protein Sci, 2009. **18**(5): p. 1081-94.
- 427 48. Goodsell, D.S., G.M. Morris, and A.J. Olson, *Automated docking of flexible ligands: applications*  
428 *of AutoDock*. Journal of molecular recognition, 1996. **9**(1): p. 1-5.
- 429 49. Morris, G.M., et al., *Automated docking using a Lamarckian genetic algorithm and an empirical*  
430 *binding free energy function*. 1998. **19**(14): p. 1639-1662.
- 431 50. Van Der Spoel, D., et al., *GROMACS: fast, flexible, and free*. Journal of computational chemistry,  
432 2005. **26**(16): p. 1701-1718.
- 433 51. Schuttelkopf, A.W. and D.M. van Aalten, *PRODRG: a tool for high-throughput crystallography of*  
434 *protein-ligand complexes*. Acta Crystallogr D Biol Crystallogr, 2004. **60**(Pt 8): p. 1355-63.
- 435 52. Xue, L.C., et al., *PRODIGY: a web server for predicting the binding affinity of protein-protein*  
436 *complexes*. Bioinformatics, 2016. **32**(23): p. 3676-3678.
- 437 53. David, C.C. and D.J. Jacobs, *Principal component analysis: a method for determining the essential*  
438 *dynamics of proteins*. Methods Mol Biol, 2014. **1084**: p. 193-226.


- 439 54. Amadei, A., A.B. Linssen, and H.J. Berendsen, *Essential dynamics of proteins*. Proteins, 1993.  
440 **17**(4): p. 412-25.
- 441 55. Maisuradze, G.G. and D.M. Leitner, *Free energy landscape of a biomolecule in dihedral principal*  
442 *component space: sampling convergence and correspondence between structures and minima*.  
443 Proteins, 2007. **67**(3): p. 569-78.
- 444 56. Altis, A., et al., *Construction of the free energy landscape of biomolecules via dihedral angle*  
445 *principal component analysis*. J Chem Phys, 2008. **128**(24): p. 245102.
- 446 57. Miszkiel, A., M. Wojciechowski, and S. Milewski, *Long range molecular dynamics study of*  
447 *regulation of eukaryotic glucosamine-6-phosphate synthase activity by UDP-GlcNAc*. Journal of  
448 Molecular Modeling, 2011. **17**(12): p. 3103-3115.
- 449 58. Maisuradze, G.G. and D.M. Leitner, *Free energy landscape of a biomolecule in dihedral principal*  
450 *component space: Sampling convergence and correspondence between structures and minima*.  
451 Proteins-Structure Function and Bioinformatics, 2007. **67**(3): p. 569-578.
- 452 59. Paoloni-Giacobino, A., et al., *Cloning of the Tmprss2 gene, which encodes a novel serine*  
453 *protease with transmembrane, LDLRA, and SRCR domains and maps to 21q22.3*. Genomics,  
454 1997. **44**(3): p. 309-20.
- 455 60. Neitzel, J.J.J.N.E., *Enzyme catalysis: the serine proteases*. 2010. **3**(9): p. 21.

456



467

468



469


470 Fig. SF2: Ramachandran plot of modeled Tmprss2

471

472

473


474



475

476 Fig. SF3: PCA analysis of TMPRSS2-Ligand complexes. Here we can observe that TMPRSS2 in  
477 apo-form, and with ligands like Carvacrol, BDMC and Thymol showed a big free energy cluster  
478 with several small clusters. TMPRSS2 with p-Cymene, Thymoquinone and limonene showed  
479 several small free energy clusters with no distinct big cluster whereas TMPRSS2 with  $\beta$ -  
480 Caryophyllene and Camostat exhibit three medium sized cluster with few small clusters.

481



482

483

484 Fig. SF4: FEL for Tmprss2 with rejected phytochemicals/ligands. Extracted frames from the  
 485 larger two clusters to show the changes in the interaction pose of the ligands with Tmprss2.

486 **Supplementary Tables**487 **Supplementary Table ST2:** Non-bonded interaction of carvacrol with TMPRSS2 (shown in  
488 Fig. 4)

Sl. No.	TMPRSS2	Carvacrol	Distance (Å)	Type of Interaction
1	GLN438:O	O1	2.48	H-Bond
2	ILE381:CD	Pi-Orbitals	3.82	Hydrophobic
3	CYS465:SG	Pi-Orbitals	3.63	Hydrophobic
4	VAL402	C11	4.69	Hydrophobic
5	CYS465	C11	4.29	Hydrophobic
6	LYS390	C5	4.77	Hydrophobic
7	CYS437	C5	4.29	Hydrophobic
8	CYS465	C5	3.66	Hydrophobic
9	ILE381	C4	4.89	Hydrophobic
10	VAL402	Pi-Orbitals	5.33	Hydrophobic
11	CYS437	Pi-Orbitals	5.43	Hydrophobic

489 **Supplementary Table ST3:** Non-bonded interaction of thymol with TMPRSS2 (shown in Fig.  
490 4)

Sl. No.	TMPRSS2	Thymol	Distance (Å)	Type of Interaction
1	CYS465:N	O1	3.18	H-Bond
2	ILE381	C4	4.39	Hydrophobic
3	CYS437	C4	4.99	Hydrophobic
4	CYS465	C5	4.47	Hydrophobic
5	TYR474	C5	4.13	Hydrophobic

491 **Supplementary Table ST4:** Non-bonded interaction of BDMC with TMPRSS2 (shown in Fig.  
492 4)

Sl. No.	TMPRSS2	BDMC	Distance (Å)	Type of Interaction
1	GLN438:N	O2	2.91	H-Bond
2	ASP440:OD2	O4	2.61	H-Bond
3	ALA400	Pi-Orbitals	4.30	Hydrophobic
4	VAL402	Pi-Orbitals	5.42	Hydrophobic
5	VAL434	Pi-Orbitals	4.97	Hydrophobic
6	CYS437	Pi-Orbitals	4.84	Hydrophobic
7	CYS465	Pi-Orbitals	4.76	Hydrophobic

493

494